45% Hit the Bariatric Surgery Threshold in Lilly's Retatrutide Trial

Eli Lilly's retatrutide achieved ≥30% body weight loss in 45.3% of TRIUMPH-1 trial participants over 80 weeks. This responder rate—not just the 28.3% mean—signals efficacy across the population, not pulled by outliers. Payers and formulary committees weight population-level outcomes heavily in cost-effectiveness models. That metric often drives coverage decisions more aggressively than average improvement alone, making retatrutide's distribution pattern a commercial pressure point.